Zürich (ots) - Zartes Licht, weiche Haut, reizender Stoff: Mit grossflächigen Kampagnen startet die ...
Helsinn Healthcare Licenses a Supportive Care Product from Roche
Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss
pharmaceutical group, and ROCHE today announced the signing of a
licensing agreement, granting HELSINN HEALTHCARE the worldwide rights
for the patented, phase II product, NETUPITANT. Netupitant is a
potent and selective NK-1 receptor antagonist, developed as NKE by
Roche, for the prevention of chemotherapy-induced nausea and vomiting
"We are delighted to strengthen our long lasting partnership with Roche and enter into this new agreement for Netupitant." said Enrico Braglia, Managing Director of HELSINN HEALTHCARE SA, "Our successful collaboration with Roche in the anti-emetic arena started in 1998 with the licensing of Palonosetron (AloxiÒ), a strong and long acting 5-HT3 receptor antagonist for the prevention of CINV and PONV (post operative nausea and vomiting). The new acquisition of Netupitant is an excellent opportunity to boost our AloxiÒ franchise. Helsinn intends to complete the development of Netupitant in order to bring to the physicians and their patients a novel and effective emesis treatment".
"Helsinn has significant experience in developing emesis products for oncology patients. Roche is pleased to continue our relationship with Helsinn through their further development of Netupitant," said Peter Hug, Roche's Head of Pharma Partnering.
About NK-1 receptor antagonists
NK-1 receptor antagonists are antiemetics that work by blocking the action of neurokinin-1 (Substance P), a natural substance in the brain that causes emesis. In the clinic, it has been demonstrated that NK-1 receptor antagonists, administered in conjunction with a 5-HT3 receptor antagonist, are significantly more effective in the control of both acute and delayed nausea and vomiting compared with 5-HT3 receptor antagonists alone.
About HELSINN HEALTHCARE
HELSINN HEALTHCARE SA is a privately owned pharmaceutical group with headquarters in Switzerland. HELSINN's core business is the licensing of pharmaceuticals in niche therapeutic areas. The company's business strategy is to in-license early-stage new chemical entities and complete their development from the performance of pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic markets (U.S. and Europe). HELSINN's products are eventually out-licensed to its marketing partners for distribution. The active pharmaceutical ingredients and the finished dosage forms are manufactured at HELSINN's cGMP facilities and supplied worldwide to its customers. For more information about HELSINN, please visit www.helsinn.com.
ots Originaltext: Helsinn Healthcare SA
Contact person HELSINN:
Alex Bossi, Director BD & Licensing-in